JP2018523996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523996A5 JP2018523996A5 JP2017567686A JP2017567686A JP2018523996A5 JP 2018523996 A5 JP2018523996 A5 JP 2018523996A5 JP 2017567686 A JP2017567686 A JP 2017567686A JP 2017567686 A JP2017567686 A JP 2017567686A JP 2018523996 A5 JP2018523996 A5 JP 2018523996A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- tumor
- dendritic cells
- dendritic cell
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004443 dendritic cell Anatomy 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 239000002243 precursor Substances 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 230000004041 dendritic cell maturation Effects 0.000 claims description 12
- 238000012258 culturing Methods 0.000 claims description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 8
- -1 imidazoquinoline compound Chemical class 0.000 claims description 8
- 239000003104 tissue culture media Substances 0.000 claims description 8
- 102000004889 Interleukin-6 Human genes 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 102000004890 Interleukin-8 Human genes 0.000 claims description 6
- 108090001007 Interleukin-8 Proteins 0.000 claims description 6
- 230000024245 cell differentiation Effects 0.000 claims description 6
- 229940100601 interleukin-6 Drugs 0.000 claims description 6
- 229940096397 interleukin-8 Drugs 0.000 claims description 6
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 239000002158 endotoxin Substances 0.000 claims description 4
- 229940124669 imidazoquinoline Drugs 0.000 claims description 4
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 4
- 210000001165 lymph node Anatomy 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 230000003100 immobilizing effect Effects 0.000 claims description 3
- 230000028709 inflammatory response Effects 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 2
- 230000005975 antitumor immune response Effects 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000002421 cell wall Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000004700 fetal blood Anatomy 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 210000005166 vasculature Anatomy 0.000 claims description 2
- HQBUPOAKJGJGCD-UHFFFAOYSA-N 3h-imidazo[4,5-c]quinolin-4-amine Chemical compound NC1=NC2=CC=CC=C2C2=C1N=CN2 HQBUPOAKJGJGCD-UHFFFAOYSA-N 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021191885A JP2022023248A (ja) | 2015-06-30 | 2021-11-26 | 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞 |
| JP2024089927A JP2024101059A (ja) | 2015-06-30 | 2024-06-03 | 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187086P | 2015-06-30 | 2015-06-30 | |
| US62/187,086 | 2015-06-30 | ||
| PCT/US2016/040134 WO2017004230A1 (en) | 2015-06-30 | 2016-06-29 | Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021191885A Division JP2022023248A (ja) | 2015-06-30 | 2021-11-26 | 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018523996A JP2018523996A (ja) | 2018-08-30 |
| JP2018523996A5 true JP2018523996A5 (enExample) | 2019-08-15 |
| JP6985939B2 JP6985939B2 (ja) | 2021-12-22 |
Family
ID=57609106
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567686A Active JP6985939B2 (ja) | 2015-06-30 | 2016-06-29 | 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞 |
| JP2021191885A Withdrawn JP2022023248A (ja) | 2015-06-30 | 2021-11-26 | 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞 |
| JP2024089927A Pending JP2024101059A (ja) | 2015-06-30 | 2024-06-03 | 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021191885A Withdrawn JP2022023248A (ja) | 2015-06-30 | 2021-11-26 | 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞 |
| JP2024089927A Pending JP2024101059A (ja) | 2015-06-30 | 2024-06-03 | 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11124768B2 (enExample) |
| EP (2) | EP3317403B1 (enExample) |
| JP (3) | JP6985939B2 (enExample) |
| KR (1) | KR102763373B1 (enExample) |
| CN (2) | CN114774356A (enExample) |
| AR (1) | AR106496A1 (enExample) |
| AU (2) | AU2016286112B2 (enExample) |
| CA (1) | CA2990640A1 (enExample) |
| ES (1) | ES3032055T3 (enExample) |
| IL (2) | IL312668A (enExample) |
| MX (2) | MX2018000056A (enExample) |
| PL (1) | PL424035A1 (enExample) |
| RU (1) | RU2018103235A (enExample) |
| WO (1) | WO2017004230A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018160666A1 (en) * | 2017-02-28 | 2018-09-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Short-term activated dc1s and methods for their production and use |
| CA3157004A1 (en) * | 2019-10-07 | 2021-04-15 | Northwest Biotherapeutics, Inc. | In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response |
| CN117417886B (zh) * | 2023-10-20 | 2024-05-14 | 广东壹加再生医学研究院有限公司 | 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法 |
| CN119286782B (zh) * | 2024-12-11 | 2025-04-04 | 上海赛笠百傲生物医药有限公司 | 一种高效诱导外周血来源单核细胞至不成熟树突状细胞的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0633929T3 (da) | 1992-04-01 | 2004-06-28 | Univ Rockefeller | Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener |
| US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| US20020094545A1 (en) | 2000-11-30 | 2002-07-18 | Harris Paul E. | Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads |
| WO2003010292A2 (en) | 2001-07-25 | 2003-02-06 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
| EP2322603B1 (en) * | 2001-09-06 | 2019-10-16 | NorthWest Biotherapeutics, Inc. | Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response |
| HUE031517T2 (en) | 2002-06-19 | 2017-07-28 | Northwest Biotherapeutics Inc | Cross-flow filtration equipment and procedures for leukocyte enrichment |
| WO2004053072A2 (en) * | 2002-12-06 | 2004-06-24 | Northwest Biotherapeutics, Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| DK1604016T3 (da) * | 2003-02-27 | 2009-05-18 | Northwest Biotherapeutics Inc | In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler |
| KR100887560B1 (ko) | 2007-04-24 | 2009-03-09 | 크레아젠 주식회사 | 준성숙 수지상 세포를 포함하는 류마티스 관절염 치료용약제학적 조성물 |
| EP3375868A1 (en) * | 2007-11-08 | 2018-09-19 | Dana Farber Cancer Institute, Inc. | Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28 |
| EP2072617A1 (en) | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
| ES2686708T3 (es) | 2008-04-18 | 2018-10-19 | Baxter International Inc. | Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición |
| US10238723B2 (en) * | 2013-03-14 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer |
-
2016
- 2016-06-29 CN CN202210272735.4A patent/CN114774356A/zh active Pending
- 2016-06-29 KR KR1020187002974A patent/KR102763373B1/ko active Active
- 2016-06-29 WO PCT/US2016/040134 patent/WO2017004230A1/en not_active Ceased
- 2016-06-29 EP EP16818706.0A patent/EP3317403B1/en active Active
- 2016-06-29 US US15/740,094 patent/US11124768B2/en active Active
- 2016-06-29 AU AU2016286112A patent/AU2016286112B2/en active Active
- 2016-06-29 JP JP2017567686A patent/JP6985939B2/ja active Active
- 2016-06-29 CA CA2990640A patent/CA2990640A1/en active Pending
- 2016-06-29 IL IL312668A patent/IL312668A/en unknown
- 2016-06-29 MX MX2018000056A patent/MX2018000056A/es unknown
- 2016-06-29 IL IL256522A patent/IL256522B2/en unknown
- 2016-06-29 PL PL424035A patent/PL424035A1/pl unknown
- 2016-06-29 CN CN201680038886.6A patent/CN107849537A/zh active Pending
- 2016-06-29 EP EP25161616.5A patent/EP4574159A3/en active Pending
- 2016-06-29 RU RU2018103235A patent/RU2018103235A/ru not_active Application Discontinuation
- 2016-06-29 ES ES16818706T patent/ES3032055T3/es active Active
- 2016-06-30 AR ARP160101986A patent/AR106496A1/es unknown
-
2018
- 2018-01-08 MX MX2023001622A patent/MX2023001622A/es unknown
-
2021
- 2021-09-17 US US17/477,949 patent/US20220145246A1/en active Pending
- 2021-11-26 JP JP2021191885A patent/JP2022023248A/ja not_active Withdrawn
-
2023
- 2023-05-12 AU AU2023202977A patent/AU2023202977A1/en active Pending
-
2024
- 2024-06-03 JP JP2024089927A patent/JP2024101059A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005121256A (ru) | Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей | |
| Weiner | The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides | |
| JP2018523996A5 (enExample) | ||
| JP2024019229A (ja) | 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法 | |
| JP2024101059A (ja) | 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞 | |
| JP2018537949A5 (enExample) | ||
| Mohty et al. | Leukemic dendritic cells: potential for therapy and insights towards immune escape by leukemic blasts | |
| JP2022552200A (ja) | 樹状細胞およびＴ細胞の活性化を増強するためのならびにＴＨ－１免疫応答を誘導するためのｉｎ ｖｉｔｒｏの方法および組成物 | |
| WO2001062092A1 (en) | Formulations and methods for using the same to elicit an immune response | |
| HK40072988A (en) | Activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers | |
| JPWO2021071977A5 (enExample) | ||
| HK40085184A (en) | In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response | |
| HK1258885B (en) | Methods relating to activated dendritic cell compositions for subjects with advanced cancers | |
| BR112017028602B1 (pt) | Método para produzir células dendríticas humanas isoladas parcialmente maduras e ativadas, e uso de uma composição farmacêutica compreendendo células dendríticas humanas parcialmente maduras e ativadas | |
| WO2002078698A2 (fr) | Polarisation de cellules dendritiques (traitement des infections, du cancer et des maladies auto-immunes) par l'histamine |